Auszug wichtiger Publikationen
- Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist. 2011;16(5):602-13. doi: 10.1634/theoncologist.2011-0002. Epub 2011 Apr 5.
- Niederle MB, Niederle B. Gastric neuroendocrine tumors. Endoscopic and surgical treatment. Chirurg. 2011 Jul;82(7):574-82. doi: 10.1007/s00104-011-2068-x. Review.
- Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010 Oct 5;17(4):909-18. doi: 10.1677/ERC-10-0152. Print 2010 Dec.
- Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R, Grossman A; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135-56. doi: 10.1159/000335629. Epub 2012 Feb 15.
- Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158.
- Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Raderer M, Trattnig S, Herneth A, Karanikas G. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol. 2013 Jul;23(7):1978-85. doi: 10.1007/s00330-013-2785-2. Epub 2013 Mar 8.
- Fiebiger W, Kasere K, Rödler S, Oberbauer R, Bauer C, Raderer M. Neuroendocrine carcinomas arising in solid organ transplant recipients: rare but aggressive malignancies. Oncology 2009; 77:314 – 7
- Schindl M, Kaczirek K, Passler C, Kaserer K, Prager G, Scheuba C, Raderer M, Niederle B. Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? World J Surg. 2002 Aug;26(8):976-84. Epub 2002 May 21.
- Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001 Jan;136(1):49-54.
- Raderer M, Kurtaran A, Leimer M, Angelberger P, Niederle B, Vierhapper H, Vorbeck F, Hejna MH, Scheithauer W, Pidlich J, Virgolini I. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol. 2000 Mar;18(6):1331-6.
- Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg. 2000 Nov;24(11):1312-8.
- Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P, Hübsch P, Dvorak M, Valent P, Niederle B. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med. 1998 Sep;39(9):1575-9.
- Schindl M, Niederle B, Häfner M, Teleky B, Längle F, Kaserer K, Schöfl R. Stage-dependent therapy of rectal carcinoid tumors. World J Surg. 1998 Jun;22(6):628-33; discussion 634.
- Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994 Oct 27;331(17):1116-21.